Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study digs into cancer treatment failures in poorer nations

NCT ID NCT07246213

Knowledge-focused Sponsor: Resonance, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will look back at the medical records of 18,000 children, teens, and young adults with cancer treated in five low- and middle-income countries. The goal is to measure how often treatment fails or causes serious side effects, especially for leukemia and lymphoma. No new drugs or treatments are being tested — instead, researchers hope to find patterns that can guide future efforts to improve care in places where resources are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify key barriers and gaps in cancer care in low-resource settings, pointing toward practical interventions to improve survival.
What could go wrong
This is a retrospective chart review, not a treatment trial. It cannot prove what works, only describe what happened. Results may not apply to other regions or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 18,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will comprise pediatric patients aged 0-21 years diagnosed with cancer, reflecting diverse demographic backgrounds and clinical characteristics.

Ages

0 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects must meet all the following criteria to be included in this registry: 1. Participants must be willing and able to provide informed consent prior to enrollment in the registry. 1. For minors or individuals unable to provide informed consent, assent must be obtained along with consent from a legal guardian. 2. Note: Exemption applies to this criterion when waiver of informed consent/assent is granted by Institutional Review Board(IRB)/Independent Ethics Committee(IEC)/Competent Authorities(CAs). 2. A confirmed diagnosis of any type of cancer within the 15 years prior to the site's activation date. 3. Age 0 to 21 years at the time of diagnosis. 4. Received substantial anti-cancer treatment at the participating center, including but not limited to: 1. Chemotherapy 2. Surgery 3. Radiation therapy 4. Immunotherapy 5. Medical records are available and accessible for review Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from this registry: 1. Patients who only visited the participating center for: 1. Consultation without subsequent primary anti-cancer treatment at the participating center 2. Pathology, radiology, or other diagnostic evaluations without treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia childhood malignant neoplasm lymphoblastic lymphoma neoplasm Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute lymphoblastic leukemia Acute lymphoblastic leukemia (ALL) Adolescent cancer Childhood cancers Lymphoblastic lymphoma Lymphoblastic lymphoma (LBL) Young adult cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fundación Ayúdame a Vivir

    NOT_YET_RECRUITING

    El Salvador, El Salvador, 1101, El Salvador

  • Hospital Escuela

    NOT_YET_RECRUITING

    Tegucigalpa, Distrito Central, 11101, Honduras

  • Hospital Mario Catarino Rivas

    NOT_YET_RECRUITING

    San Pedro Sula, Cortés Department, 21102, Honduras

  • Unidad Nacional de Oncología Pediátrica (UNOP)

    RECRUITING

    Guatemala City, Guatemala

  • Yeolyan Center for Cancer and Blood Disorders

    RECRUITING

    Yerevan, Armenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.